Three broker downgrades
Three broker downgrades
About this video
Rudi Filapek-Vandyck from FNArena shares his insights into recent broker moves. His focus is on Cochlear (COH) and its strong share price performance. But Morgan Stanley (MS) seems to have taken a step back to a neutral hold, preparing investors for a less exuberant outlook.
Meanwhile, in the broader healthcare sphere, UBS has downgraded its rating from outperform to neutral for both Cochlear (COH) and Metcash (MTS) due to disappointing results.
In another news, avocados could be giving a boost to Costa Group (CGC), however, Macquarie seems to believe that a private equity firm won't lower its takeover offer, despite speculation otherwise.
Finally, let's not forget about ResMed (RMD) which Rudi says seems to have stirred value investors. Whether this trend will continue, only time will tell.